Drug Trial Radar · NCT05201079
Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Oct 29, 2021
Primary completion
Nov 15, 2023
Study completion Nov 15, 2023
Sponsor
- Lead sponsor
- Mikrobiomik Healthcare Company S.L.Industry
- Sponsor type
- Industry
- First posted
- Jan 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with microbiota alterations developed after being exposed to antibiotics are especially susceptible to Clostridioides difficile infections (CDI). The incidence and severity of CDI has increased in recent years and CDI recurrences (r-CDI) due to the appearance of new episodes in patients with a previous cured CDI, represent a serious and complex clinical issue. Although antibiotics are the recommended therapy for the first episode of CDI, treatment with oral vancomycin and/or metronidazole often results in significant treatment failure. In addition, the treatment of r-CDI is not adequately standardized, and although the most widely used treatment is the administration of fidaxomicin and bezlotoxumab, its efficacy in patients who already have r-CDI is not proven. In the late years, Fecal Microbiota Transfer (FMT) has emerged as the preferred non-pharmacological treatment to manage CDI with multiple recurrences and recent clinical trials have evaluated its potential efficacy and safety in the treatment of patients with primary CD infection. The objective of this study is to assess the efficacy and safety of the MBK-01 medication, consisting of heterologous lyophilized fecal microbiota capsules coming from healthy donors in comparison to the treatment with fidaxomicin, in 92 patients with primary or r-CDI.
Conditions
- Recurrent Clostridium Difficile Infection
- Primary Clostridium Difficile Infection
Interventions
MBK-01Biological
A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
FidaxomicinDrug
Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the TreatmentTime frame: 8 weeks after the start of the treatment
- Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 72 Hours After the Start of the TreatmentTime frame: 72 hours after the start of the treatment
- Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 3 Weeks After the Start of the TreatmentTime frame: 3 weeks after the start of the treatment
- Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 3 Months After the Start of the TreatmentTime frame: 3 months after the start of the treatment
- Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 6 Months After the Start of the TreatmentTime frame: 6 months after the start of the treatment
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Hospital General Universitario de Alicante
Alicante, Spain
Hospital Universitario de Cruces
Barakaldo, Spain
Hospital Quirónsalud Barcelona
Barcelona, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Universitario de Donostia
Donostia / San Sebastian, Spain
Hospital Josep Trueta de Gerona
Girona, Spain
Hospital San Pedro
Logroño, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Universitario Quirónsalud Madrid
Madrid, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Hospital Universitario de Araba
Vitoria-Gasteiz, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.